Corrigendum: Probiotics for the treatment of docetaxel-related weight gain of breast cancer patients—A single-center, randomized, double-blind, and placebo-controlled trial
Zhang Juan1 
Zhang Qing2 
Liang Yongping3 Liyuan Qian2 Wei Wu2 Yanguang Wen2 Jianbin Tong4,5,6 Boni Ding2*- 1Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei, China
- 2Department of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University, Changsha, China
- 3Department of Medical Imaging (Ultrasound), Tangshan Central Hospital, Tangshan, China
- 4Hunan Province Key Laboratory of Brain Homeostasis, Third Xiangya Hospital, Central South University, Changsha, China
- 5Center for Experimental Medicine, Third Xiangya Hospital, Central South University, Changsha, China
- 6Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha, China
by Juan, Z., Qing, Z., Yongping, L., Qian, L., Wu, W., Wen, Y., Tong, J., and Ding, B. (2021). Front. Nutr. 8:762929. doi: 10.3389/fnut.2021.762929
In the published article, there was an error in affiliation [1]. Instead of “Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha, China”, it should be “Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei, China”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: docetaxel-related weight gain, breast cancer, docetaxel-based chemotherapy, gut microbiota, metabolism
Citation: Juan Z, Qing Z, Yongping L, Qian L, Wu W, Wen Y, Tong J and Ding B (2023) Corrigendum: Probiotics for the treatment of docetaxel-related weight gain of breast cancer patients—A single-center, randomized, double-blind, and placebo-controlled trial. Front. Nutr. 10:1276556. doi: 10.3389/fnut.2023.1276556
Received: 12 August 2023; Accepted: 14 August 2023;
Published: 22 August 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Juan, Qing, Yongping, Qian, Wu, Wen, Tong and Ding. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Boni Ding, 275878133@qq.com